Sygen Pharmaceuticals Ltd (Nigeria) and ORx Pharmaceuticals Corp. (Canada) join forces to create Sygen-ORx Bioscience that accelerates healthcare development in Africa.

ORX Pharmaceuticals, a member of the Toronto Institute of Pharmaceutical Technology, North America’s premier post-secondary institution for pharmaceutical technology and research, is known for its commitment to advancing medical science and improving patient care. , brings a wealth of experience and patented drug technology. development and business. Led by a team of dedicated professionals and guided by a vision of excellence, ORX consistently delivers revolutionary treatments in a variety of therapeutic areas, earning recognition as a leader in the pharmaceutical industry.

Sygen Pharmaceuticals, known for its pioneering spirit and unwavering dedication to science, complements ORX’s strengths with its innovative approach to solving health problems. With a focus on developing quality medicines and improving access to new treatments, Sygen has established itself as a trusted partner in driving positive change in the healthcare environment in Nigeria.

The joint venture between ORx and Sygen represents a strong union of vision, expertise, and commitment to improving patient outcomes and addressing medication safety issues. By combining resources, knowledge, and capabilities, Sygen-ORx aims to accelerate the development and commercialization of innovative therapies, address unmet medical needs and improve access to healthcare for patients worldwide.

According to the draft agreement, the joint venture will be called Sygen-ORx Biosciences Ltd.

The joint venture will focus on the following:

The development of improved generic pharmaceuticals, focusing on products that have proven clinical efficacy and have received regulatory approval and significant commercial success.

* To promote new drug discovery programs in the regional and global pharmaceutical market.

* Reduce costs and increase access to High Quality Prescribed Medicines in Africa In addition to establishing a joint venture, Sygen and ORx will provide support to the joint venture by using their knowledge gained from global research in drug discovery and development and commercialization and distribution, with the aim of accelerating open innovation during early drug discovery.

“Sygen-ORx Biosciences will build on the foundation of excellence established by ORx and Sygen, ushering in a new era of healthcare innovation,” said Dr Alexander MacGregor. [ORx Pharmaceuticals CEO]”With a shared commitment to scientific excellence and integrity. Sygen-ORX Biosciences is set to have a major impact in the healthcare space, creating the future of medicine for generations to come”.

“Collaboration is central to our mission at Sygen Pharmaceuticals, and we are excited to embark on this transformational journey with ORx Pharmaceuticals,” said Charles Ogunwuyi, [Sygen Pharmaceutical CEO] “Together, as Sygen ORx, we have the opportunity to expand our impact and advance innovation in healthcare, and ultimately improve the lives of African patients even more.

By partnering with ORx Pharmaceuticals, we can leverage our combined strengths to deliver effective solutions that solve critical medical problems and advance patient care.